We are committed to transforming the lives of millions of people through science and innovation. For the last 300 years we have been helping millions of people do more, feel better and live longer, working across many disease areas to discover new medicines and vaccines that have changed or cured disease.
Our research is centred around science related to the immune system, the use of genetics, and advanced analytics in development. This combination of science and technology generates new insights to direct our focus, improve our probability of success and most importantly brings new medicines to patients.
The company currently (as of Q2 2018) has 27 immunomodulatory NMEs (new molecular entities) in the clinic, representing 60% of the total clinical pipeline. Of these 27 assets, more than half are potential first-in-class therapy options for a range of different diseases.
We partner with over a thousand companies, academic institutions and research charities to explore new drugs and accelerate drug development. This includes a new partnership with 23andMe, the world’s leading consumer genetics research company, which grants our researchers access to databases that can be used to evaluate the links between genetic variations and human disease.
Find out more
We share expertise, resources, intellectual property and know-how with external researchers and the scientific community to promote change beyond GSK
Sharing our research
We are committed to reporting the results of clinical research that evaluates our medicines and vaccines
Trials in people
Find out about our clinical trials process, how we work with doctors and volunteers, and how to become a research volunteer
Our use of animals
At GSK we believe we have a moral responsibility to ensure good welfare and treatment of the animals in our care